Eric Wachter - Provectus Biopharmaceutica CTO and Executive VP
| PVCTDelisted Stock | USD 0.11 0.00 0.00% |
CTO
Dr. Eric A. Wachter Ph.D., is Chief Technology Officer of the Company. Prior to that served as Executive Vice President Pharmaceuticals and as a member of our board of directors since we acquired PPI on April 23, 2002 until May 14, 2012. Prior to joining us, from 1997 to 2002 he was a senior member of the management team of Photogen, including serving as Secretary and a director of Photogen since 1997 and as Vice President and Secretary and a director of Photogen since 1999. Prior to joining Photogen, Dr. Wachter served as a senior research staff member with Oak Ridge National Laboratory. He earned a Ph.D. in Chemistry from the University of WisconsinMadison in 1988. since 2018.
| Age | 60 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 866 594 5999 |
| Web | https://www.provectusbio.com |
Provectus Biopharmaceutica Management Efficiency
The company has return on total asset (ROA) of (1.8529) % which means that it has lost $1.8529 on every $100 spent on assets. This is way below average. Provectus Biopharmaceutica's management efficiency ratios could be used to measure how well Provectus Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Provectus Biopharmaceuticals currently holds 2.29 M in liabilities with Debt to Equity (D/E) ratio of 0.25, which may suggest the company is not taking enough advantage from borrowing. Provectus Biopharmaceutica has a current ratio of 0.26, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Provectus Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Provectus Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Provectus Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Provectus to invest in growth at high rates of return. When we think about Provectus Biopharmaceutica's use of debt, we should always consider it together with cash and equity.
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee. Provectus Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people. Provectus Biopharmaceuticals [PVCT] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Provectus Biopharmaceutica is listed under Pharmaceutical Products category by Fama And French industry classification. Management Performance
| Return On Asset | -1.85 |
Provectus Biopharmaceutica Management Team
Elected by the shareholders, the Provectus Biopharmaceutica's board of directors comprises two types of representatives: Provectus Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Provectus. The board's role is to monitor Provectus Biopharmaceutica's management team and ensure that shareholders' interests are well served. Provectus Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Provectus Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Heather CPA, Chief Officer | ||
| Bruce Horowitz, COO Director | ||
| Eric Wachter, CTO and Executive VP |
Provectus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Provectus Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.85 | ||||
| Operating Margin | (4.77) % | ||||
| Current Valuation | 46.73 M | ||||
| Shares Outstanding | 419.55 M | ||||
| Shares Owned By Insiders | 3.69 % | ||||
| Shares Owned By Institutions | 0.04 % | ||||
| Number Of Shares Shorted | 1.82 M | ||||
| Price To Earning | (0.48) X | ||||
| Price To Book | 5.44 X | ||||
| Price To Sales | 55.94 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |